TG THERAPEUTICS, INC. TGTX

Latest FY: 2025 Healthcare Biotechnology
Market Price $56.70
Market Cap $8.68B
P/E Ratio 20.47
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑87.3% YoY
$616.29M
3-Yr CAGR: 504.9%
Net Income ↑1,812.4% YoY
$447.18M
Net Margin: 72.6%
Free Cash Flow ↑38.4% YoY
-$24.99M
FCF Yield: -0.29%
EPS (Diluted) ↑1,746.7% YoY
$2.77
Basic: $3.10
Return on Equity Efficiency
69.0%
ROA: 42.1%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (TGTX)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $0.3M $-73.8M $-1.60 0.00% $-61.6M $-61.9M
FY 2017 $0.3M -8.8% $-112.7M $-1.91 -19.4% 0.00% $-93.8M $-93.8M -51.4%
FY 2018 $0.2M -48.4% $-166.5M $-2.30 -20.4% 0.00% $-128.9M $-129.0M -37.6%
FY 2019 $0.2M 0.0% $-159.6M $-1.96 +14.8% 0.00% $-132.8M $-132.9M -3.0%
FY 2020 $0.2M 0.0% $-232.1M $-2.42 -23.5% 0.00% $-214.5M $-214.9M -61.6%
FY 2021 $6.7M +4,300.7% $1.1M $-348.1M $-2.63 -8.7% 0.00% $-295.6M $-296.0M -37.8%
FY 2022 $2.8M -58.4% $2.5M $-198.3M +43.0% $-1.46 +44.5% 0.00% $-176.2M $-176.2M +40.5%
FY 2023 $233.7M +8,290.0% $219.5M $12.7M +106.4% $0.09 +106.2% 0.00% $-31.4M $-31.4M +82.2%
FY 2024 $329.0M +40.8% $290.5M $23.4M +84.5% $0.15 +66.7% 0.00% $-40.5M $-40.6M -29.1%
FY 2025 $616.3M +87.3% $515.6M $447.2M +1,812.4% $2.77 +1,746.7% 0.00% $-24.8M $-25.0M +38.4%
$

Valuation

Market Price $56.70
Market Cap $8.68B
Enterprise Value $8.85B
P/E Ratio 20.47
P/B Ratio 13.39
FCF Yield -0.29%
Dividend Yield N/A
Shares Outstanding 153,083,600
%

Profitability & Margins

Gross Margin 83.66%
Operating Margin 20.01%
Net Margin 72.56%
Return on Equity (ROE) 69.01%
Return on Assets (ROA) 42.06%
Asset Turnover 0.58x
Revenue 3-Yr CAGR 504.86%
🛡️

Financial Health & Liquidity

Current Ratio 4.10
Cash Ratio 0.51
Debt / Equity 0.379
Debt / Assets 0.231
Cash & Equivalents $79.15M
Total Debt $245.65M
Book Value / Share $4.23
💧

Cash Flow Efficiency

Operating Cash Flow -$24.77M
Capital Expenditures (CapEx) $214.00K
Free Cash Flow -$24.99M
OCF / Revenue -4.02%
FCF / Revenue -4.05%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $2.77
EPS (Basic) $3.10
Dividends / Share N/A
Book Value / Share $4.23
EPS YoY Growth 1,746.67%
🏛️

Balance Sheet (FY 2025)

Total Assets $1.06B
Total Liabilities $415.23M
Stockholders' Equity $648.02M
Current Assets $630.76M
Current Liabilities $153.76M